Table 11.

The FDA-approved immune checkpoint inhibitors

Target	Drugs	Indications	Company
CTLA-4	Ipilimumab	Colorectal cancer, hepatocellular carcinoma, melanoma mesothelioma, non-small cell lung cancer, renal cell carcinoma	Bristol Myers Squibb
PD-1	Cemiplimab	Basal cell carcinoma, cervical squamous cell cancer, non-small cell lung cancer	Regeneron Pharmaceuticals
	Nivolumab	Colorectal cancer, esophageal squamous cell carcinoma, hepatocellular carcinoma, gastric cancer, hodgkin lymphoma, head and neck squamous cell carcinoma, melanoma, mesothelioma, non-small cell lung cancer, renal cell carcinoma, urothelial carcinoma	Bristol Myers Squibb
	Pembrolizumab	Breast cancer, cervical cancer, colorectal cancer, esophageal squamous cell cancer, endometrial carcinoma, esophageal carcinoma, gastric carcinoma, hepatocellular carcinoma, hodgkin lymphoma, non-small-cell lung cancer, melanoma, mesothelioma, Merkel cell carcinoma, non-small cell lung cancer, primary mediastinal large B-cell lymphoma, renal cell carcinoma, small-cell lung cancer, urothelial carcinoma, biliary tract cancer	Merck & Co
	Dostarlimab -gxly	Advanced or recurrent mismatch repair-deficient/microsatellite instability-high endometrial cancer, recurrent or advanced mismatch repair-deficient solid tumors	GlaxoSmithKline
PD-L1	Atezolizumab	Breast cancer, hepatocellular carcinoma, melanoma, non-small cell lung cancer, small-cell lung cancer, urothelial, alveolar soft part sarcoma, urothelial carcinoma	Genentech
	Avelumab	Merkel cell carcinoma, renal cell carcinoma, urothelial carcinoma	EMD Serono
	Durvalumab	Non-small cell lung cancer, small-cell lung cancer, urothelial carcinoma, biliary tract cancer, hepatocellular carcinoma	AstraZeneca UK Limited

Source: All the information is derived from the United States Food and Drug Administration.gov (https://www.fda.gov/)